China's vaccine market slated to jump; Shanghai Pharma says 2014 operating revenue up 18%;

> The human vaccine market in China is slated to jump as R&D and production capacity grow. Release

> China's Lansen Pharmaceutical Holdings says 2014 turnover was up nearly 23% to $116.8 million. Release (PDF)

> China's Shanghai Pharma says operating revenue in 2014 rose 18% to $390.1 million. Release

> The China Food and Drug Administration has approved an application from Nasdaq-listed CASI Pharmaceuticals ($ENMD) to conduct a Phase II global clinical trial in ovarian clear cell carcinoma for its proprietary drug candidate ENMD-2076. Release

> HK's Lijun International Pharmaceutical says 2014 sales revenues were up 6.5% to $377 million. Release (PDF)